Los Angeles Capital Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Los Angeles Capital Management’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-10,092	Closed	-$122K	–	1459
2019 Q1	$122K	Sell	10,092 -10,252	-50%	-$151K	﹤0.01%	1331
2018 Q4	$255K	Sell	20,344 -34,186	-63%	-$472K	﹤0.01%	1147
2018 Q3	$809K	Buy	54,530 +36,620	+204%	+$576K	﹤0.01%	952
2018 Q2	$301K	Buy	+17,910	New	+$348K	﹤0.01%	1282

Other funds holding CNCE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Los Angeles Capital Management's CNCE Position: Q2 2019 in Review

Los Angeles Capital Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2019, closing a stake of 10,092 shares — an estimated $122K sold.

Los Angeles Capital Management first reported a position in CNCE in Q2 2018 and held it in 4 quarters. The position peaked at $809K in Q3 2018. 87 funds tracked by Wall St. Rank hold CNCE as of Q2 2019.

Los Angeles Capital Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
Los Angeles Capital Management sold 10,092 Concert Pharmaceuticals, Inc. shares in Q2 2019, an estimated $122K.
Los Angeles Capital Management first reported a position in Concert Pharmaceuticals, Inc. in Q2 2018 and held it in 4 quarters.
Los Angeles Capital Management's Concert Pharmaceuticals, Inc. position peaked at $809K in Q3 2018.
87 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2019.

Based on Los Angeles Capital Management's 13F filing for Q2 2019, filed 29 Jul 2019.